These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Glycomimetic-based pharmacological chaperones for lysosomal storage disorders: lessons from Gaucher, GM1-gangliosidosis and Fabry diseases. Sánchez-Fernández EM; García Fernández JM; Mellet CO Chem Commun (Camb); 2016 Apr; 52(32):5497-515. PubMed ID: 27043200 [TBL] [Abstract][Full Text] [Related]
8. A counterintuitive approach to treat enzyme deficiencies: use of enzyme inhibitors for restoring mutant enzyme activity. Fan JQ Biol Chem; 2008 Jan; 389(1):1-11. PubMed ID: 18095864 [TBL] [Abstract][Full Text] [Related]
9. Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders. Valenzano KJ; Khanna R; Powe AC; Boyd R; Lee G; Flanagan JJ; Benjamin ER Assay Drug Dev Technol; 2011 Jun; 9(3):213-35. PubMed ID: 21612550 [TBL] [Abstract][Full Text] [Related]
10. Treatment of lysosomal storage diseases: recent patents and future strategies. Ortolano S; Viéitez I; Navarro C; Spuch C Recent Pat Endocr Metab Immune Drug Discov; 2014 Jan; 8(1):9-25. PubMed ID: 24433521 [TBL] [Abstract][Full Text] [Related]
11. [Therapy of lysosomal storage diseases: update and perspectives]. Lara-Aguilar RA; Juárez-Vázquez CI; Medina-Lozano C Rev Invest Clin; 2011; 63(6):651-8. PubMed ID: 23650678 [TBL] [Abstract][Full Text] [Related]
12. Therapeutic Role of Pharmacological Chaperones in Lysosomal Storage Disorders: A Review of the Evidence and Informed Approach to Reclassification. Keyzor I; Shohet S; Castelli J; Sitaraman S; Veleva-Rotse B; Weimer JM; Fox B; Willer T; Tuske S; Crathorne L; Belzar KJ Biomolecules; 2023 Aug; 13(8):. PubMed ID: 37627292 [TBL] [Abstract][Full Text] [Related]
13. Pharmacological chaperone therapy for Gaucher disease: a patent review. Benito JM; García Fernández JM; Ortiz Mellet C Expert Opin Ther Pat; 2011 Jun; 21(6):885-903. PubMed ID: 21457079 [TBL] [Abstract][Full Text] [Related]
14. Cyclodextrin-based iminosugar click clusters: the first examples of multivalent pharmacological chaperones for the treatment of lysosomal storage disorders. Decroocq C; Rodríguez-Lucena D; Ikeda K; Asano N; Compain P Chembiochem; 2012 Mar; 13(5):661-4. PubMed ID: 22344719 [No Abstract] [Full Text] [Related]
15. Recent developments in therapeutic approaches for lysosomal storage diseases. Urbanelli L; Magini A; Polchi A; Polidoro M; Emiliani C Recent Pat CNS Drug Discov; 2011 Jan; 6(1):1-19. PubMed ID: 21073432 [TBL] [Abstract][Full Text] [Related]
16. Enzyme replacement therapy and substrate reduction therapy in lysosomal storage disorders with neurological expression. Valayannopoulos V Handb Clin Neurol; 2013; 113():1851-7. PubMed ID: 23622408 [TBL] [Abstract][Full Text] [Related]